Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

Rhea-AI Summary

Xeris Biopharma Holdings (NASDAQ: XERS) announced that CEO Paul R. Edick will present at the H.C. Wainwright BioConnect 2022 conference from January 10-13, 2022. The presentation will highlight the FDA approval of Recorlev® and other recent company developments. It will be available on-demand starting January 10, 2022, at 7:00 a.m. E.T. Xeris specializes in therapies for endocrinology, neurology, and gastroenterology, with existing products like Gvoke® and Keveyis®. The company is headquartered in Chicago, IL.

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Biopharma, will present an overview of the company and highlight recent events, including the FDA approval of Recorlev®, at the H.C. Wainwright BioConnect 2022 virtual conference being held January 10-13, 2022.

The on-demand presentation will be available beginning January 10, 2022 at 7:00 a.m. E.T. through the investors section on the Company's website at www.xerispharma.com.

About Xeris Biopharma

Xeris (Nasdaq: XERS) is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. Xeris has two commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis. In addition, Recorlev® was recently approved by the U.S. Food and Drug Administration for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.

Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005180/en/

Investor Contact

Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com

Source: Xeris Biopharma

FAQ

What will Xeris Biopharma present at the H.C. Wainwright BioConnect 2022 conference?

Xeris Biopharma will present an overview of the company and highlight the FDA approval of Recorlev®.

When is the H.C. Wainwright BioConnect 2022 conference?

The conference will be held from January 10-13, 2022.

What time will the Xeris Biopharma presentation be available?

The presentation will be available on-demand starting January 10, 2022, at 7:00 a.m. E.T.

What are Xeris Biopharma's key products?

Xeris Biopharma's key products include Gvoke® and Keveyis®, along with the recently FDA-approved Recorlev®.

What is the focus of Xeris Biopharma's therapies?

Xeris Biopharma develops therapies in endocrinology, neurology, and gastroenterology.